Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery
This study investigates the effects of gut hormones, specifically GLP-1 and DPP-4 inhibition, on food intake and glucose metabolism post-Roux-en-Y gastric bypass (RYGB). Given the rising prevalence of obesity and related metabolic disorders, successful outcomes could enhance the commercial viability of GLP-1 receptor antagonists and DPP-4 inhibitors in obesity management. The competitive landscape includes established players like Merck (sitagliptin) and Novo Nordisk (liraglutide), necessitating a thorough diligence process to assess market entry strategies and potential partnerships. The findings may also inform future product development and positioning in the obesity treatment market.
Indication: Severe Obesity
Modality: small molecule
Target: GLP-1 receptor and DPP-4 enzyme
Sponsor: Hvidovre University Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: GLP-1 receptor and DPP-4 enzyme
View original source fields
Condition raw: Severe Obesity
Condition normalized: Severe Obesity
Modality raw: small molecule
Modality normalized: small molecule
Target raw: GLP-1 receptor and DPP-4 enzyme
Target normalized: GLP-1 receptor and DPP-4 enzyme